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Abstract
Background: Yersinia pestis is the causative agent of plague and a potential agent of bioterrorism
and biowarfare. The plague biothreat and the emergence of multidrug-resistant plague underscore
the need to increase our understanding of the intrinsic potential of Y. pestis for developing
antimicrobial resistance and to anticipate the mechanisms of resistance that may emerge in Y. pestis.
Identification of Y. pestis genes that, when overexpressed, are capable of reducing antibiotic
susceptibility is a useful strategy to expose genes that this pathogen may rely upon to evolve
antibiotic resistance via a vertical modality. In this study, we explored the use of a multicopy
suppressor,  Escherichia coli host-based screening approach as a means to expose antibiotic
resistance determinant candidates in Y. pestis.
Results: We constructed a multicopy plasmid-based, Y. pestis genome-wide expression library of
nearly 16,000 clones in E. coli and screened the library for suppressors of the antimicrobial activity
of ofloxacin, a fluoroquinolone antibiotic. The screen permitted the identification of a
transcriptional regulator-encoding gene (robAYp) that increased the MIC99 of ofloxacin by 23-fold
when overexpressed from a multicopy plasmid in Y. pestis. Additionally, we found that robAYp
overexpression in Y. pestis conferred low-level resistance to many other antibiotics and increased
organic solvent tolerance. Overexpression of robAYp also upregulated the expression of several
efflux pumps in Y. pestis.
Conclusion: Our study provides proof of principle for the use of multicopy suppressor screening
based on the tractable and easy-to-manipulate E. coli host as a means to identify antibiotic resistance
determinant candidates of Y. pestis.
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Background
Yersinia pestis (Yp) is one of the most virulent known bac-
teria [1] and a potential agent of bioterrorism and biowar-
fare [2,3] included in the Category A of biological agents
for public health preparedness against bioterrorism [4].
Yp is the etiologic agent of plague, a disease responsible
for millions of human deaths during the history of civili-
zation [5,6]. Cases are reported every year in many parts
of the world [7] and the increasing number of worldwide
cases has placed plague in the category of re-emerging dis-
eases [8].
Patients with plague need prompt antibiotic treatment or
else death may be unavoidable. The aminoglycosides
streptomycin (STR) and gentamicin (GEN) are the pre-
ferred antibiotics for treatment, but a number of other
drugs are also effective [9,10]. Tetracyclines [such as dox-
ycycline (DOX)], chloramphenicol (CHL), or selected sul-
fonamides are the recommended antibiotics for
prophylactic therapy in the event of exposure or high risk
of exposure to Yp [2,9,10]. Fluoroquinolones have also
been suggested for treatment and prophylaxis and are
noted as a chemotherapeutic alternative against strains
resistant to the first line anti-plague drugs [2,10].
The threat of bioterrorism-generated plague outbreaks
with engineered (multi)drug-resistant Yp strains [2,3] and
the documented outbreak of multidrug-resistant plague
[11] underscore the need to develop alternative chemo-
therapeutic solutions to this disease. In line with this view,
we are exploring the development of anti-infectives that
target the high-affinity iron acquisition system of Yp [12-
14] and may offer novel therapeutic possibilities [15]. The
plague biothreat also underscores the need to increase our
understanding of the intrinsic potential of Yp for develop-
ing antimicrobial resistance and to anticipate the mecha-
nisms of resistance that may emerge in Yp clinical isolates
in the future. With this consideration in mind, we
explored herein the use of a multicopy suppressor screen-
ing approach as a means to expose antibiotic resistance
determinant candidates in Yp. Multicopy suppressor
screening has been useful to study potential drug targets
or mechanisms of antibiotic resistance in other species
[16]. We constructed a multicopy plasmid-based, Yp
genome-wide expression library of nearly 15,000 clones
in E. coli (Ec), a tractable and easy-to-manipulate surro-
gate bacterial host, and screened the library for suppres-
sors of the antimicrobial activity of the fluoroquinolone
antibiotic ofloxacin (OFX). Noteworthy, fluoroquinolo-
nes have been suggested by the Working Group on Civil-
ian Biodefense as alternative drugs in the event of the use
of aerosolized Yp as a bioweapon against a civilian popu-
lation [2]. The screen permitted the identification of a
gene that reduced the susceptibility of Yp to fluoroqui-
nolones and other antibiotic classes when overexpressed
from a multicopy plasmid. Our study provides proof of
principle for the utilization of multicopy suppressor
screening using an Ec host as a means to identify antibi-
otic resistance determinant candidates in Yp.
Results and Discussion
A multicopy suppressor screen led to the isolation of a Y. 
pestis genomic fragment involved in ofloxacin resistance
We constructed a plasmid-based expression library of the
Yp genome comprised of 15,648 Ec clones and screened
the library for strains with reduced OFX susceptibility. A
strain (Ec pGEM-OFXr1) selected in the screen exhibiting
reduced susceptibility that was confirmed to be plasmid-
mediated and transferable to Yp was chosen for further
characterization (Figure 1). The plasmid (pGEM-OFXr1)
carried by this strain was isolated and the restriction diges-
tion pattern and sequence of its genomic insert were
examined. This analysis revealed a 4,158-bp fragment (Yp
KIM chromosome coordinates 4,137,482 to 4,141,639)
(Figure 2). The 5' and 3' ends of the fragment included the
5' end of y3722 (creA) and the 3' end of y3727 (slt), respec-
tively. The products of creA and slt are annotated as a con-
served hypothetical protein and a putative soluble lytic
murein transglycosylase, respectively, in the Yp genome
database. The center of the fragment encompassed four
genes: y3723 (robA, herein referred to as robAYp); y3724
(gpmB); y3725; and y3726 (trpR). The products of gpmB
and  trpR  are annotated as a putative phosphoglycero-
mutase and a putative regulator of tryptophan metabo-
lism genes, respectively. The product of y3725  is
annotated as a conserved hypothetical protein. Our in sil-
ico search for conserved domains (via CD-Search; please
see Availability & requirements for more details) revealed
the presence of an NTPase (PRK05074) domain in this
protein. The NTPase domain is characteristic of proteins
with pyrophosphatase activity [17,18]. This suggested that
y3725 may be involved in nucleoside triphosphate metab-
olism. Lastly, the predicted product of robAYp (RobAYp) is
annotated as an orthologue of Ec RobA (RobAEc), a tran-
scriptional regulator of unclear physiological function
and member of the AraC/XylS family [19]. Importantly,
overexpression of robAEc and Enterobacter cloacae robA con-
fers low-level resistance in Ec and E. cloacae, respectively,
to a number of unrelated antibiotics [20-22]. Thus, the
analysis of the insert in pGEM-OFXr1 suggested that
robAYp is responsible for the reduced OFX susceptibility
observed in Ec pGEM-OFXr1 and Yp pGEM-OFXr1 (Figure
1). These results validate the utility of our library and sup-
pressor screen approach as a means to identify antibiotic
resistance determinant candidates in Yp.
Overexpression of robAYp affects susceptibility to multiple 
antibiotics
We investigated whether overexpression of robAYp alone
would reduce OFX susceptibility in Ec and, more impor-BMC Microbiology 2008, 8:122 http://www.biomedcentral.com/1471-2180/8/122
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tantly, in Yp. To this end, we evaluated the antibiotic sus-
ceptibility of Ec pGEM-RobYp and Yp pGEM-RobYp. These
test strains carried pGEM-RobYp, a plasmid constructed by
inserting the fragment encompassing robAYp and its pro-
moter region (identified by using the robAEc promoter as
reference [23]) into the vector pGEM-4Z. The antibiotic
susceptibilities of these test strains were compared to that
of the corresponding Ec pGEM-4Z and Yp pGEM-4Z con-
trol strains. These control and test strains were isogenic,
except for the lack of the plasmid-borne robAYp, and their
growth in ampicillin (AMP)-containing liquid media was
indistinguishable from that of their cognate test strains
(not shown). A first examination of Ec pGEM-RobYp and
Yp pGEM-RobYp indicated that these strains retained the
reduced OFX susceptibility phenotype seen in Ec pGEM-
OFXr1 and Yp pGEM-OFXr1 on solid media (Figure 1),
thus indicating that robAYp alone was sufficient to reduce
OFX susceptibility. In view of this, we conducted further
OFX susceptibility testing in liquid media. In addition, we
compared the susceptibility of the test and control strains
to two other fluoroquinolones [ciprofloxacin (CIP) and
levofloxacin (LVX)], a quinolone (NAL), and antibiotics
of other classes, including two tetracyclines [tetracycline
(TET) and DOX], four aminoglycosides [STR, GEN, kan-
amycin (KAN), and apramycin (APR)], and CHL.
The IC50 and MIC99 values determined for the aforemen-
tioned antibiotics are shown in Table 1. Comparison of
the OFX IC50 and OFX MIC99 values of the test strains and
their respective control strains revealed that overexpres-
sion of robAYp reduced OFX susceptibility in both Yp and
Ec. In Yp, robAYp overexpression increased OFX IC50 and
OFX MIC99 values by 5-fold and 23-fold, respectively. The
IC50 and MIC99 values of CIP, LVX, and NAL also increased
significantly (3- to 5-fold change range) in Yp  pGEM-
RobYp compared with Yp pGEM-4Z. The reduced OFX and
LVX susceptibility of Yp pGEM-RobYp was also revealed by
time-kill experiments described below. In Ec, robAYp over-
expression produced an increase in the IC50 and MIC99 of
the fluoroquinolone antibiotics (2- to 4-fold change
range), but had no significant effect (<2-fold change) on
NAL susceptibility.
In both Yp and Ec, robAYp overexpression also correlated
with an increase in the IC50 and MIC99 of the two tetracy-
clines tested and CHL (2- to 7-fold change range). No sub-
stantial impact (<2-fold change) on the MIC99 values of
four aminoglycosides tested was detected in Yp upon over-
expression of robAYp. Interestingly, however, the IC50 val-
Reduction of ofloxacin susceptibility conferred by plasmids  pGEM-OFXr1 and pGEM-RobYp Figure 1
Reduction of ofloxacin susceptibility conferred by 
plasmids pGEM-OFXr1 and pGEM-RobYp. E. coli (Ec) 
and Y. pestis (Yp) strains were streaked on solid media with-
out or with ofloxacin: 0.35 μg/ml (the concentration used in 
the screen) for E. coli and 0.15 μg/ml for Y. pestis. Ampicillin 
(100 μg/ml) was also added to the media for plasmid-carrying 
strains.
Genetic map of the robAYp-containing region of the Y. pestis KIM chromosome and inserts of pGEM-OFXr1 and pGEM-RobYp Figure 2
Genetic map of the robAYp-containing region of the Y. pestis KIM chromosome and inserts of pGEM-OFXr1 and 
pGEM-RobYp.BMC Microbiology 2008, 8:122 http://www.biomedcentral.com/1471-2180/8/122
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ues of these aminoglycosides were reproducibly and
consistently lower (2- to 3-fold reduction range) in Yp
pGEM-RobYp compared with Yp pGEM-4Z. These results
indicated that robAYp overexpression increased the suscep-
tibility of Yp to aminoglycosides. The hypersensitivity of
Yp pGEM-RobYp to aminoglycosides was also observed in
time-kill experiments described below. Aminoglycoside
hypersensitivity was not observed in Ec pGEM-RobYp. On
the contrary, the strain had a modest decrease in the sus-
ceptibility to GEN, STR, and KAN (2- to 3-fold change
range) relative to Ec pGEM-4Z.
Overall, the phenotypic comparison of the antibiotic sus-
ceptibility of pGEM-RobYp-bearing strains and pGEM-4Z-
bearing strains clearly demonstrates that robAYp overex-
pression affects antibiotic susceptibility in both Yp and Ec,
yet in a noticeably species-specific manner. As discussed
below, the effects on antibiotic susceptibility induced by
robAYp overexpression are likely due to an upregulation of
efflux pumps. Thus, the species-specific differences in
antibiotic susceptibility are probably produced by species-
specific differences in efflux pump upregulation.
Overexpression of robAYp in Y. pestis reduces killing by 
fluoroquinolones but enhances killing by aminoglycosides
The comparative analysis of IC50  and MIC99  values
described above indicated that Yp  pGEM-RobYp  has
reduced fluoroquinolone susceptibility and increased
aminoglycoside susceptibility compared with Yp pGEM-
4Z. To further probe these phenotypes, we examined the
killing kinetics of these two strains when exposed to OFX,
CIP, STR, and GEN (Figure 3). The profiles of the time-kill
curves for OFX and CIP demonstrated that the Yp pGEM-
4Z control was more rapidly killed by the fluoroquinolo-
nes than Yp pGEM-RobYp. Conversely, the profiles of the
time-kill curves for STR and GEN revealed that Yp pGEM-
RobYp was more rapidly killed by the aminoglycosides
than the Yp pGEM-4Z control. Both strains had compara-
ble growth in the absence of fluoroquinolone or
aminoglycoside antibiotics during the time frame of the
time-kill assays. The contrasting effects of robAYp overex-
pression on fluoroquinolone- and aminoglycoside-medi-
ated killing are consistent with the results of the
comparative analysis of IC50 and MIC99 values (Table 1).
The observed aminoglycoside hypersensitivity is some-
Table 1: Effect of robAYp overexpression on antibiotic susceptibility
IC50 (μg/ml)a FCc MIC99 (μg/ml)b FC
Y. pestis no plasmid pGEM-4Z pGEM-RobYp no plasmid pGEM-4Z pGEM-RobYp
Ofloxacin 0.01 0.01 0.05 5 0.03 0.03 0.7 23
Ciprofloxacin 0.009 0.009 0.04 4 0.02 0.02 0.09 5
Levofloxacin 0.01 0.01 0.04 4 0.02 0.02 0.09 5
Nalidixic Acid 0.5 0.8 2 3 2 2 6 3
Chloramphenicol 0.3 0.4 0.9 2 1 1 3 3
Tetracycline 0.7 1 6 6 1 3 10 3
Doxycycline 0.4 0.5 1 2 0.6 1 3 3
Kanamycin 1 0.9 0.4 0.4 2 2 2 1
A p r a m y c i n 2 31 0 . 3 6 64 0 . 7
Streptomycin 1 2 0.8 0.4 3 3 3 1
Gentamicin 0.4 0.4 0.2 0.5 1 0.4 0.4 1
E. coli no plasmid pGEM-4Z pGEM-RobYp no plasmid pGEM-4Z pGEM-RobYp
Ofloxacin 0.03 0.04 0.09 2 0.08 0.2 0.4 2
Ciprofloxacin 0.01 0.009 0.04 4 0.05 0.08 0.2 3
Levofloxacin 0.04 0.04 0.1 3 0.2 0.2 0.4 2
Nalidixic Acid 27 26 28 1 83 100 100 1
Chloramphenicol 0.3 0.3 0.8 3 2 2 13 7
Tetracycline 0.8 0.6 2 3 3 3 10 3
Doxycycline 0.3 0.2 0.6 3 1 0.6 3 5
Kanamycin 2 1 2 2 10 6 6 1
Apramycin 3 3 4 1 21 17 21 1
Streptomycin 3 2 3 2 17 13 13 1
Gentamicin 0.9 0.6 2 3 6 5 8 2
a IC50 values were calculated from sigmoidal curves fitted to triplicate sets of dose-response data. b MIC99 values are means of triplicates. c Fold 
change (FC) values were calculated as the ratio of the IC50 or MIC99 of the pGEM-RobYp transformants to the IC50 or MIC99 of the pGEM-4Z 
transformants. IC50, MIC99, and FC values <1 and values >1 were rounded to one significant digit and to the nearest non-fractional number, 
respectively.BMC Microbiology 2008, 8:122 http://www.biomedcentral.com/1471-2180/8/122
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what unexpected and contrasts with both the reduced sus-
ceptibility observed for all other antibiotics tested and the
increased tolerance to organic solvents described below.
Overexpression of robAYp increases tolerance to organic 
solvents
We investigated whether robAYp overexpression affected
the susceptibility of Yp  and Ec to O2
.--generating com-
pounds (paraquat, menadione, and plumbagin), heavy
metals (zinc, cobalt, and copper), and organic solvents (n-
pentane, n-hexane, cyclohexane, p-xylene, and diphenyl
ether). No effect on the susceptibility to O2
.--generating
compounds, cobalt, and copper was observed (not
shown). Conversely, overexpression of robAYp drastically
increased organic solvent tolerance in both Yp and Ec (Fig-
ure 4) and reduced the susceptibility of Yp to zinc (not
shown). Overexpression of robAYp increased the tolerance
of Yp to n-hexane and cyclohexane and the tolerance of Ec
to cyclohexane and n-pentane. All the Yp and Ec strains
were resistant to diphenyl ether and sensitive to p-xylene.
Ec was also resistant to n-hexane, a result that is in agree-
ment with previous reports [24]. These findings parallel
the reduction of organic solvent susceptibility induced by
robAEc overexpression in Ec [21].
Overexpression of robAYp in Y. pestis induces changes in 
efflux pump gene expression
In Ec, the RobAEc-induced multidrug resistance and sol-
vent tolerance phenotypes have been shown to be largely
dependent on the upregulation of the multidrug efflux
pump AcrAB, which belongs to the resistance-nodulation-
cell division (RND) superfamily [25,26]. With this prece-
dent in mind, we compared the expression of genes
belonging to 34 drug efflux pumps between Yp pGEM-
RobYp and Yp pGEM-4Z using quantitative real-time PCR
(qRT-PCR). These pumps were identified using a variety
of bioinformatic approaches (see Methods) to compile an
extensive list that included most, if not all, putative drug
efflux pump systems encoded in the genome of Yp. It is
worth mentioning as a reference that there are 37 drug
efflux pumps annotated in the Ec genome [27,28]. Our
expression analysis detected transcripts for 33 of the 34
genes investigated and revealed that four efflux pumps
Effect of robAYp overexpression on the rate of Y. pestis killing  by fluoroquinolones and aminoglycosides Figure 3
Effect of robAYp overexpression on the rate of Y. pestis 
killing by fluoroquinolones and aminoglycosides. Yp 
pGEM-RobYp (overexpressing robAYp) and Yp pGEM-4Z (vec-
tor control) were treated with the indicated antibiotics at 5 
× MIC99. The means of triplicate treated cultures were plot-
ted and standard error bars are shown.
Effect of robAYp overexpression on organic solvent tolerance Figure 4
Effect of robAYp overexpression on organic solvent 
tolerance. Cultures of Y. pestis (Yp) and E. coli (Ec) strains 
carrying the plasmids indicated were spotted on solid 
medium. The surface of the medium was overlaid with the 
organic solvent and growth was recorded after incubation. 
H, n-hexane; CH, cyclohexane; P, n-pentane; X, p-xylene; DE, 
diphenyl ether; -, no solvent control.BMC Microbiology 2008, 8:122 http://www.biomedcentral.com/1471-2180/8/122
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were significantly upregulated (≥ 5-fold change) in Yp
pGEM-RobYp  compared with Yp  pGEM-4Z (Table 2).
Interestingly, two of these upregulated pumps (y3392-
y3393  and  y1050-y1049) are Ec  AcrAB homologs. The
other two upregulated pumps (y2173 and y0010) belong
to the major facilitator superfamily (MFS). The transcript
level of hasF (y3516), encoding the ortholog of Ec TolC,
which is the outer membrane protein channel that part-
ners with Ec  AcrAB and other RND and MFS pumps
[29,30], was drastically upregulated as well (5.8-fold
change; not shown).
Inspection of the promoter regions upstream of the upreg-
ulated genes in Yp pGEM-RobYp revealed the presence of a
putative RobAEc binding site in each of these regions (Fig-
ure 5). These results suggest that RobAYp may act as a pos-
itive regulator for the y0010, y1050-y1049,  y2173  and
y3392-y3393 systems. This possible regulatory scenario is
consistent with the upregulation in the expression levels
of these pumps induced by robAYp overexpression in Yp.
It is likely that the multidrug resistance and solvent toler-
ance phenotypes induced by robAYp overexpression are
Table 2: Effect of robAYp overexpression on the transcript levels of efflux pump genes in Y. pestis
Gene namea University of Wisconsinb TIGR SANGER Pump family or protein functionc FCd
(floR) y2173 NT02YP2579 YPO2148 MFS 12.7 ± 2.5
(yieO) y0010 NT02YP0010 YPO0009 MFS 8.6 ± 1.1
(acrA*-acrB) y3392*-y3393 NT02YP4041 YPO1000 RND 6.9 ± 0.4
acrA*-acrB y1050*-y1049 NT02YP1227 YPO3132 RND 5.0 ± 0.4
(acrA*-acrB) y3760*-y3759 NT02YP4463 YPO0420 RND 2.7 ± 0.1
- y4041 NT02YP4789 YPO4020 DMT 1.7 ± 0.9
yegM*-yegN-yegO-yegB y1386*-y1385-y1384-y1383 NT02YP1646 YPO2847 RND 1.4 ± 0.5
(ybjY*-ybjZ) y2814*-y2813 NT02YP3366 YPO1364 ABC 1.4 ± 0.4
(acrA*-acrB) y0702*-y0703 NT02YP0804 YPO3483 RND 1.3 ± 0.3
emrA*-emrB y0922*-y0921 NT02YP1066 YPO3267 MFS 1.3 ± 0.4
(macA*-macB) y1481*-y1480 NT02YP1756 YPO2999 RND 1.3 ± 0.5
ygeD y3180 NT02YP3786 YPO0792 MFS 1.3 ± 0.2
fieF y0060 NT02YP0067 YPO0077 CDF 1.2 ± 0.1
(abgT) y3402 NT02YP4052 YPO1008 IT 1.1 ± 0.2
acrD y1439 NT02YP1705 YPO3043 RND 1.1 ± 0.1
sugE y0613 NT02YP0702 YPO0355 SMR 1.1 ± 0.4
(ynfM) y2108 NT02YP2497 YPO2266 MFS 1.1 ± 0.4
bcr y2916 NT02YP3488 YPO1267 MFS 1.1 ± 0.3
aaeA*-aaeB y0178*-y0177 NT02YP0192 YPO3685 ArAE 1.1 ± 0.0
(yjcR*-Q) y3558*-y3559 NT02YP4231 YPO0619 RND 1.0 ± 0.2
yajR y1017 NT02YP1187 YPO3169 MFS 1.0 ± 0.1
arsB y0844 NT02YP0968 YPO3347 IT 1.0 ± 0.4
corC y1191 NT02YP1397 YPO2617 HCC 0.9 ± 0.1
mdtJ*-mdtI y2242*-y2241 NT02YP2670 YPO2068 SMR 0.8 ± 0.2
rosA y1087 NT02YP1268 YPO3093 MFS 0.8 ± 0.1
ydhC y1948 NT02YP2306 YPO2389 MFS 0.8 ± 0.2
y3186 NT02YP3792 YPO0798 MFS 0.7 ± 0.1
(ydhE) y1945 NT02YP2302 YPO2392 MATE 0.7 ± 0.1
(ybeQ) y1874 NT02YP2220 YPO1712 MFS 0.7 ± 0.0
mdlA*-mdlB y1039*-y1040 NT02YP1213 YPO3145 ABC 0.7 ± 0.0
ydeF y2653 NT02YP3168 YPO1515 MFS 0.5 ± 0.1
emrE, gacE y2000 NT02YP2368 YPO2333 SMR 0.5 ± 0.0
mdfA, cmr y4067 NT02YP4824 YPO4048 MFS 0.2 ± 0.0
(ydjV) y2272 NT02YP2703 YPO2040 MFS nd
a Gene name as annotated for Y. pestis strain KIM and/or CO92 or gene names (in parentheses) given herein based on the name of their E. coli 
homologs. Multiple names for the same gene are separated by commas. Genes of multi-component pumps are separated by dashes. The star (*) 
marks genes from multi-component pump gene clusters whose transcripts were analyzed by qRT-PCR. b Gene designations in the University of 
Wisconsin, TIGR, and SANGER Y. pestis genome databases. The Wisconsin column shows designations for all the genes in each predicted multi-
component pump. TIGR and SANGER columns show only genes targeted in qRT-PCR. c Pump families assigned based on homology to known 
(super)family members from other organisms. MFS, major facilitator superfamily; SMR, small multidrug resistance family; ABC, ATP-binding cassette 
superfamily; RND, resistance-nodulation-cell division superfamily; MATE, multidrug and toxic compound extrusion family; DMT, drug/metabolite 
transporter superfamily; CDF, cation diffusion facilitator family; ArAE, aromatic acid exporter family; IT, Ion transporter superfamily; HCC, HlyC/
CorC family. d Fold change values (FC) are means of triplicates ± standard errors and are presented in decreasing order. For polycistronic 
transcripts, qRT-PCR was conducted with primers targeting the first pump component-encoding gene of the operon. These genes are marked with 
a star. nd, transcript not detected in any of the three Y. pestis strains examined (wild-type, Yp pGEM-4Z, and Yp pGEM-RobYp).BMC Microbiology 2008, 8:122 http://www.biomedcentral.com/1471-2180/8/122
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due, at least in part, to increases in compound extrusion
by one or more of the upregulated pumps mentioned
above. This idea is supported by the reported observation
that the RobAEc-induced multidrug resistance and solvent
tolerance in Ec is largely dependent on the AcrAB-TolC
efflux pump system [25,26].
Conclusion
The identification of Yp genes that, when overexpressed,
are capable of reducing antibiotic susceptibility is a useful
strategy to expose genes that this pathogen may rely upon
to evolve resistance via a vertical modality. In this study,
we explored the use of a multicopy suppressor, Ec host-
based screening approach as a means to identify antibiotic
resistance determinant candidates in Yp. To seek proof of
principle for this approach, we constructed a multicopy
plasmid-based,  Yp  genome-wide expression library of
nearly 16,000 clones in Ec and screened this library for
suppressors of the antimicrobial activity of the fluoroqui-
nolone antibiotic OFX. The screen permitted the identifi-
cation of a gene that, when overexpressed, reduces the
susceptibility of Yp not only to OFX, but also to other
(fluoro)quinolones, tetracyclines and CHL. This gene
(robAYp) encodes a putative transcriptional regulator, and
our results clearly demonstrate that its overexpression in
Yp and Ec confers low-level resistance to multiple antibi-
otics. Overexpression of robAYp also increases organic sol-
vent tolerance in both Yp  and  Ec  and reduces the
susceptibility of Yp to zinc.
The molecular mechanism by which overexpression of
robAYp leads to a reduction in the susceptibility to antibi-
otics and other compounds remains to be determined.
Our results indicate that overexpression of robAYp induces
a drastic upregulation in the transcript levels of four of the
34 predicted efflux pump gene systems and of hasF (tolC)
in Yp. Increased expression of chromosomally encoded
efflux pumps is a known cause of multidrug resistance in
many bacteria [30]. Thus, it is likely that the reduction in
the susceptibility to antibiotics and other compounds
induced by robAYp overexpression is due, at least in part, to
multidrug efflux pump-mediated increases in compound
extrusion.
Overall, our findings provide proof of principle for the
utilization of an Ec host-based suppressor screen to iden-
tify antibiotic resistance determinant candidates in Yp.
This methodology will be useful in the identification of
genetic determinants involved in target-dependent and
target-independent resistance to antimicrobials with
known and unknown mechanisms of action. Identifica-
tion of such genetic determinants will provide first
insights to guide further studies to obtain mechanistic
information on novel modes of antimicrobial activity and
antimicrobial resistance.
Methods
Construction of genomic library
Unless otherwise indicated, all molecular biology and
microbiological manipulations were conducted using
standard procedures [31] and reagents acquired from New
England Biolabs or Sigma-Aldrich. Genomic DNA from
the avirulent Yp strain KIM6+ [32] was used for the library.
This strain lacks the Lcr virulence plasmid [5] and is
excluded from the Select Agent Program (please see Avail-
ability & requirements for more details). Genomic DNA
was prepared using AquaPure™ Genomic DNA Isolation
Kit (Bio-Rad Laboratories) and partially digested with
BsrFI, which, on average, cleaves the genome of Yp every
~760 bp. Independent partial digestions were resolved by
agarose gel electrophoresis and the fragment populations
in the 4,000-bp to 8,000-bp range were purified using
QIAquick Gel Extraction Kit (Qiagen). The fragments were
ligated to the multicopy plasmid vector pGEM-4Z
(Promega) linearized with XmaI and dephosphorylated
with calf intestine alkaline phosphatase. Genes inserted
into pGEM-4Z can be transcribed from the gpt-lac hybrid
promoter located at the 5'-end of the cloning site and,
potentially, from their native promoters. Ligations were
transformed into Ec DH5α (Invitrogen) and transform-
ants were selected in Luria-Bertani (LB) agar plates con-
taining AMP (100 μg/ml) and 5-bromo-4-chloro-3-
indolyl-β-D-galactopyranoside (40 μg/ml) for blue/white
colony screening [31]. White colonies were streaked onto
the same medium to verify their white phenotype and
15,648 confirmed white clones were independently
grown in AMP-containing LB broth in 96-well plates. After
plate incubation for culture growth to early stationary
phase, aliquots from each of the 96 cultures of each plate
were pooled, cells from each pool were harvested, and
plasmids from each pool were purified using QIAprep
Spin Miniprep Kit (Qiagen). The cultures in the plates
Potential RobA binding sites in the promoter regions of  genes upregulated in robAYp-overexpressing Y. pestis Figure 5
Potential RobA binding sites in the promoter regions 
of genes upregulated in robAYp-overexpressing Y. pes-
tis. The consensus shown is the 20-bp asymmetric marbox 
consensus sequence determined by Martin et al., 1999 [37]. R 
= A or G, Y = C or T, W = A or T, and N = A, T, G, C. Col-
umn C is the number of bp's in agreement with the 20-bp 
consensus sequence. The location of each RobA binding site 
with respect to the first codon of its cognate gene is indi-
cated by the numbers flanking the putative binding site.BMC Microbiology 2008, 8:122 http://www.biomedcentral.com/1471-2180/8/122
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were supplemented with glycerol (25%) and this master
library was stored at -70°C. Agarose gel electrophoresis
analysis confirmed plasmid population heterogeneity and
restriction digestion analysis of plasmids from several
clones verified insert diversity (not shown). The library
provides a theoretical ~760-fold genome coverage. Our in
silico BsrFI restriction analysis of the Yp genome revealed
the presence of four BsrFI fragments of ≥ 8,000 bp. These
fragments, which add up to 39,118 bp, are unlikely to be
represented in the library.
Multicopy suppressor screening
The library was replicated using a 96-pin inoculator
(Clonemaster™; Immusine Laboratories, Inc.) to inoculate
96-well plates loaded with fresh culture medium (150 μl/
well). After plate incubation for culture growth (9 h,
37°C, 200 rpm), the 15,648 cultures were pooled and the
cells of the pool were harvested. The pooled cells were
resuspended in fresh medium (1/10 × pool's volume)
containing AMP (100 μg/ml) and glycerol (25%), and the
suspension was aliquoted (1 ml library stock aliquots)
and stored at -70°C. Multicopy suppressor gene-contain-
ing clones were screened for by plating a 1/100 dilution of
a library stock aliquot on LB agar plates containing AMP
(100 μg/ml) and OFX at the MIC (0.35 μg/ml). The OFX
MIC was determined by plating Ec carrying pGEM-4Z (Ec
pGEM-4Z) on LB agar plates containing AMP (100 μg/ml)
and OFX at increasing concentrations and defined as the
concentration for which no colonies were obseved after
plate incubation (37°C, 48 h). Clones identified in the
screen were streaked on plates containing AMP (100 μg/
ml) and OFX (0.35 μg/ml) to confirm their resistant phe-
notype. The plasmid from each confirmed clone was iso-
lated and transformed into Ec and Yp. Each transformant
was streaked on AMP and OFX-containing plates [LB agar
for Ec and tryptose blood agar base (TBA; Difco Laborato-
ries) for Yp] to ascertain whether the resistance was plas-
mid mediated. The insert of each plasmid conferring
resistance was sequenced using M13 forward and reverse
universal primers (Invitrogen). The sequences obtained
were used as queries in sequence similarity searches
against the Yp KIM genome using BLAST (please see Avail-
ability & requirements for more details) to determine the
genome fragment carried by the plasmid.
Construction of pGEM-RobYp and transformation of Y. 
pestis
The fragment encompassing Yp robA (herein referred to as
robAYp) and its promoter region was PCR-amplified from
plasmid pGEM-OFXr1 (see results) with primers Robfor1
and Robrev1 (Table 3). The PCR product (1030 bp) was
cloned into pCR2.1-TOPO (TOPO TA Cloning Kit, Invit-
rogen) and the fidelity of the insert was verified by DNA
sequencing. The insert was recovered from the pCR2.1-
TOPO clone as an EcoRI fragment and sub-cloned into the
Table 3: Oligonucleotides used in this study
Namea Sequence
Robfor1 5'-TCTAGACGCTTTTTAACACACTGTACCAGT-3'
Robrev1 5'-GAATTCATTTAGATATGCCAGCACTTGATGA-3'
16sRNAF 5'-ATGACCAGCCACACTGGAACTGA-3'
16sRNAR 5'-TGACTTAACAAACCGCCTGCGT-3'
y3392F 5'-AGCGGCACCTTGGTCAATATTGT-3'
y3392R 5'-CAATTTGGTTATCCACCGATTCA-3'
y1050F 5'-GCTTATGACAGTGCAAAAGGTGA-3'
y1050R 5'-GATTAATGCGTGCAGACTCCAGT-3'
y0702F 5'-TATACCCAAGTGCGGGCACCCAT-3'
y0702R 5'-CATTCGCTACTGTGTCATTGCCT-3'
y3402F 5'-TCGATGCCACTGAATAGCGATCT-3'
y3402R 5'-ATCTGGTGAACGCAATAACGAGT-3'
y1439F 5'-CAGCCATCAAGAGGCTGCCCCAA-3'
y1439R 5'-ACCAAAGGCATCGACGCTGCCGA-3'
y1087F 5'-GGTGCTATCAGCGTATCTCACCT-3'
y1087R 5'-CCATACCGATGGGTAATGAGTAT-3'
y0060F 5'-GCAACCTGCTGATGAAGAACATA-3'
y0060R 5'-CACGAATCGCCTGACTGTGTGTT-3'
y0844F 5'-CGTTGCTAAACCGACTGGGTGAA-3'
y0844R 5'-TTGCGACAAAACATGCAGCCACA-3'
y0922F 5'-CGGCAGTGTGGTCAGTGTTCATT-3'
y0922R 5'-CACCCGACGCTTCAGGTCATTTT-3'
y1191F 5'-TCCTTAACCAGCTCTTCCACGGT-3'
y1191R 5'-CTTTATCTTCGCTGATCACCGGA-3'
y1386F 5'-GTGGTCAGGACACTAGCCATGGT-3'
y1386R 5'-CCTGCGTCAGTTGGACTTCGTAA-3'
y1481F 5'-AAAGCACAGAAGCAGGTGACTGT-3'
y1481R 5'-TTGTTGCTGACGCTGGTAGGTGA-3'
y1874F 5'-TTACCGACTATCGCACGTGACCT-3'
y1874R 5'-TTGTAGCACACGGGCAAACGTCA-3'
y1945F 5'-CCTGATGATGAGATGGTACGTAA-3'
y1945R 5'-TGAACTGAAGTTGAGGGCAATCT-3'
y2242F 5'-TTTAGTGACACTGATTGGTGGGA-3'
y2242R 5'-CATGATGCTCACCTGACTCAACA-3'
y3180F 5'-GGTAATGATGGTGGCTAATGGTT-3'
y3180R 5'-CAACCGAGCCAAGTAAGATCGCA-3'
y3558F 5'-GCCATTGATCCTGTTATCGGCTA-3'
y3558R 5'-ATAGGGAACAGATGAATGCCACA-3'
y4041F 5'-TTACGACCACAACGGTAGATGAA-3'
y4041R 5'-CATTGGTGCGGCAAGGTTCATAT-3'
y4067F 5'-GATATGATCCAGCCAGGTATGCT-3'
y4067R 5'-GCACCGATAAAGCACAAGCCAAT-3'
y0010F 5'-TCGCCGAAAGCCTTAACCGTTCT-3'
y0010R 5'-CCGAGAACGCACTAAGAAAGCCA-3'
y0178F 5'-TTTACCGCAGACGTGGTCGCTAT-3'
y0178R 5'-CCTACTGGACTCCCGTTGCTTCT-3'
y0613F 5'-GGGCTATTGGCCTGAAGTATTCT-3'
y0613R 5'-AAGCTTAGTATCCGCGCCAGACT-3'
y1017F 5'-AAATGACTCCGCTAGAGCTTCGA-3'
y1017R 5'-GGTTTACGACCGATACGATCAGA-3'
y1039F 5'-GCCGTGAATGGCACCGTTATGTA-3'
y1039R 5'-AGTTTGCCGACTCAGCTGACGAT-3'
y1948F 5'-CTGCCTGTAGTGCTGGCTTCTTT-3'
y1948R 5'-AGTACAGGGCAATCATGCTGCCA-3'
y2000F 5'-TGGCGATTATTGCCGAAGTGGTT-3'
y2000R 5'-AAAGGTGGCAGCGATTGAGACCA-3'
y2108F 5'-GGTTGTATATCAGCGGTAGTTCT-3'
y2108R 5'-TTGCACGAAAGTGTTTAGACGCT-3'
y2173F 5'-ACAAGGTGTCTCGGTATGCTGCA-3'BMC Microbiology 2008, 8:122 http://www.biomedcentral.com/1471-2180/8/122
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EcoRI site of pGEM-4Z using Ec DH5α as host. A clone
with robAYp in the same orientation as the lacZ gene of
pGEM-4Z was designated pGEM-RobYp. pGEM-RobYp and
pGEM-4Z were introduced into avirulent Yp by electropo-
ration as reported earlier [33] to create strains Yp pGEM-
RobYp  and  Yp  pGEM-4Z, respectively. Yp  strains were
grown in heart infusion broth (HIB; Difco Laboratories)
and on TBA plates without or with antibiotics as appropri-
ate.
MIC99 and IC50 determinations
Dose-response experiments were done in triplicate and
using 96 well plate-based microdilution assays as reported
[12,14]. Briefly, wells contained 200 μl of broth (LB for Ec,
HIB for Yp) inoculated with 104 cfu/ml and supplemented
with AMP (100 μg/ml) and a second antimicrobial com-
pound at the concentration indicated below. Antimicro-
bial compounds were added from stock solutions in
water, ethanol, or DMSO. Control cultures lacking the
antimicrobial compounds contained water (2%), ethanol
(1%), or DMSO (0.5%). After incubation (37°C, 200
rpm, 24 h for Yp and 16 h for Ec), growth was measured
as optical density (A620) using a Spectra Max Plus spectro-
photometer plate reader (Molecular Dynamics). IC50 val-
ues were calculated from sigmoidal curves fitted to
triplicate sets of dose-response data using KaleidaGraph
(Synergy Software). MIC99 values were calculated as the
lowest concentration tested that inhibited growth by ≥
99%. The range of concentrations tested were: OFX
(Sigma), 2.5-0.001 μg/ml; KAN (Shelton Scientific), 50-
0.024 μg/ml; CHL (Calbiochem), 10-0.005 μg/ml for Yp
and 25-0.012 μg/ml for Ec; TET (Sigma), 40-0.020 μg/ml;
APR (Sigma), 50-0.024 μg/ml; NAL (Sigma), 25-0.012 μg/
ml for Yp and 400-0.195 μg/ml for Ec; STR (Sigma), 50-
0.024 μg/ml for Yp and 100-0.049 μg/ml for Ec; GEN (EM
Science), 25-0.012 μg/ml for Yp and 50-0.024 μg/ml for
Ec; DOX (Sigma), 10-0.005 μg/ml; CIP (Fluka), 0.75-
0.0004 μg/ml for Yp and 1.25-0.0006 μg/ml for Ec; LVX
(Fluka), 0.75-0.0004 μg/ml for Yp and 1.25-0.0006 μg/ml
for Ec; plumbagin (Sigma), 50-0.024 μg/ml for Yp and
200-0.098 μg/ml for Ec; menadione (Sigma), 50-0.024
μg/ml for Yp  and 400-0.195 μg/ml for Ec; paraquat
(Sigma), 200-0.098 μg/ml for Yp and 400-0.195 μg/ml for
Ec; CoCl2 (Sigma), 1-0.0005 mg/ml; CuSO4 (Sigma), 2-
0.001 mg/ml for Yp  and 4-0.002 mg/ml for Ec; ZnCl2
(Sigma), 1-0.0005 mg/ml.
Organic solvent tolerance assay
The test for solvent tolerance was conducted essentially as
reported previously [21]. Overnight cultures of Ec and Yp
strains grown in LB broth and HIB, respectively, were
inoculated (1%) into fresh media and allowed to grow to
A620 = 0.4. Then, 5 μl of each culture were spotted on solid
medium (LB agar for Ec, TBA for Yp) with 100 μg/ml AMP
for transformants carrying pGEM plasmids or without
antibiotic for other strains. The surface of the medium was
then overlaid with the organic solvent (7 ml) to a thick-
ness of ~3 mm. The plates were sealed and incubated for
24 h for Ec strains and 48 h for Yp strains before naked-eye
examination for bacterial growth.
Time-kill experiments
Yp pGEM-RobYp and Yp pGEM-4Z (control) were treated
with STR, GEN, OFX, or CIP at 5 × MIC99. The MIC99 val-
ues were those determined using Yp pGEM-4Z in the dose-
response experiments above (5 × MIC99 values: STR, 15.6
μg/ml; GEN, 5.2 μg/ml; OFX, 0.17 μg/ml; CIP, 0.12 μg/
ml). For each antibiotic tested, three tubes with 10 ml of
preheated (37°C) HIB containing AMP (100 μg/ml) were
inoculated with 10 μl of an overnight culture of the corre-
sponding Yp strain and incubated at 37°C with shaking at
200 rpm for 2 h. After incubation, a sample of each culture
was taken and cfu/ml were determined by plating serial
dilutions on TBA plates containing AMP (100 μg/ml) and
enumerating colonies after plate incubation. Immediately
after culture sampling, the test antibiotic was added (from
stock solutions in water for GEN and STR or stock solu-
tions in DMSO for OFX and CIP) and the cultures were
returned to incubation (37°C, 200 rpm). Samples from
these cultures were then taken at time points 0 (immedi-
ately after antibiotic addition), 30, 60, 90, 120, 180, 240,
300, 360, and 420 min for cfu/ml determination as above.
Triplicate control cultures where water or DMSO was
added in place of the antibiotic solution were included in
the experiments and treated and analyzed in the same way
as the antibiotic-treated cultures. The time-kill data were
plotted using Kaleidagraph (Synergy software).
Isolation of total RNA and qRT-PCR
Yp and Ec were cultured in HIB and LB broth, respectively.
AMP (100 μg/ml) was added to the medium for strains
carrying pGEM-RobYp or pGEM-4Z. Cultures were incu-
y2173R 5'-ATAATGCCAGGAACCAGAACGCT-3'
y2272F 5'-TTGGTATCGCAAGCTCGAAGCTT-3'
y2272R 5'-TCGCATTAGCATCCCGGTGACAA-3'
y2653F 5'-ATGACCGTCAATGCGACCATCGT-3'
y2653R 5'-AATGGCCATTGCCAGCATCCATA-3'
y2814F 5'-TCTGGACCAGGCAGTAACCGATT-3'
y2814R 5'-TACTCATATCGGCCAGGGTCAGA-3'
y2916F 5'-CCTTGGGTTGTTGTCGATGCTGA-3'
y2916R 5'-ACATGCCATACCTGCAAGCGCAA-3'
y3186F 5'-GTCAGTTGGACGTTACTGCTAAT-3'
y3186R 5'-CTTTCTTGCCATAAGCGACGACA-3'
y3760F 5'-TCTGGATATTCGCCGTGCAGAGA-3'
y3760R 5'-CGTGGTAAACAGACGCTCTGGAA-3'
y3516F 5'-TGCAACGACTAACCTGTATCAGT-3'
y3516R 5'-TTTGGCGAGTAGTATTCTCTGGT-3'
a Primers used for qRT-PCR were named according to the University 
of Wisconsin gene designations for the Y. pestis KIM genome, except 
for 16sRNAF-R (used to amplify 16s rRNA).
Table 3: Oligonucleotides used in this study (Continued)BMC Microbiology 2008, 8:122 http://www.biomedcentral.com/1471-2180/8/122
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bated (37°C, 200 rpm) until they reached A620 of ~0.5
before RNA was isolated using the RiboPure-Bacteria Kit
(Ambion) according to the manufacturer's instructions.
RNA was isolated from triplicate cultures and treated with
DNase I (Ambion) (4 units, 37°C, 30 min) in DNase I
Buffer (Ambion). After the treatment, DNase I was inacti-
vated by adding DNase Inactivation Reagent (Ambion) at
20% of the final volume of RNA treated. The inactivation
was allowed to proceed at room temperature for 2 min.
The RNA sample was then centrifuged at maximum speed
in a microcentrifuge for 1 min to pellet the inactivation
reagent. The RNA was then transferred to a new RNase-
free microcentrifuge tube. cDNA was prepared from each
RNA sample using TaqMan® Reverse Transcription Rea-
gents Kit (Applied Biosystems) according to the manufac-
turer's instructions. Each cDNA sample was analyzed in
triplicate by qRT-PCR using SYBR®  Green Master Mix
(Applied Biosystems) according to the manufacturer's
instructions. cDNA was kept undiluted for qRT-PCR anal-
ysis of robA cDNA and diluted 1:5 for analysis of other
cDNAs. qRT-PCR and target sequence relative quantifica-
tion were carried out using a 384-multiwell platform with
an ABI-PRISM 7900 HT Sequence Detection System
(Applied Biosystems) as described previously [34,35]. The
thermocycling program included 1 cycle of 95°C for 5
min followed by 40 cycles of 95°C for 30 sec, 55°C for 30
sec, and 72°C for 1 min. Relative quantification was con-
ducted using the standard equation 2-ΔΔCT {i.e. 2- [(CT of target
cDNA in sample1-CT of 16S rRNA cDNA in sample 1)-(CT of target cDNA in sam-
p l e  2 - C T  o f  1 6 S  r R N A  c D N A  i n  s a m p l e  2 ) ] } [36]. The equation
expresses n-fold difference of the target cDNA in the sam-
ple from the strain carrying pGEM-RobYp (sample 1) rela-
tive to the target cDNA in the sample from the strain
carrying pGEM-4Z (sample 2, control) with normaliza-
tion to an endogenous control (16S rRNA cDNA). The
cycle threshold (CT) values utilized in the equation were
the average of three independent cultures of the same
strain, each analyzed in triplicate by qRT-PCR.
Identification of putative drug efflux pumps and RobAYp 
binding sites
Searches for efflux pumps were conducted in the
sequenced genomes of Yp KIM and and Yp CO92 (please
see Availability & requirements for more details). The
search included the following strategies. First, the tables of
functional classes in the genome websites were examined
for annotated pumps. Second, the navigator function in
the Artemis genome viewer software (please see Availabil-
ity & requirements for more details) was used to search for
the terms multidrug, efflux, transport, translocase, pump,
and drug resistance as qualifiers in the annotated genome
sequences. Third, the names of annotated Ec multidrug
efflux pumps were used as search keywords using the nav-
igator function in Artemis to find potential pumps not yet
identified with the other strategies. Fourth, all putative
pumps identified in Yp  KIM were used as queries in
BLASTP-based searches against the Yp CO92 genome and
vice versa. Fifth, annotated Ec multidrug efflux pumps were
used as queries in BLASTP-based searches against the Yp
KIM and Yp  CO92 genomes. Potential RobAEc binding
sites were searched for using the navigator function in
Artemis and the naked eye.
Abbreviations
AMP: ampicillin; APR: apramycin; CHL: chlorampheni-
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floxacin; MDR: multidrug-resistant; MFS: major facilitator
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TBA: tryptose blood agar base; TET: tetracycline; Yp: Y. pes-
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